Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of the Causes and Disease Processes of Chronic Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00001183
Recruitment Status : Completed
First Posted : November 4, 1999
Last Update Posted : October 14, 2020
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) )

Brief Summary:

Chronic lung diseases are disorders associated with abnormalities in any of the structures involved in the process of breathing and bringing oxygen into the lungs and blood. This includes abnormalities in the airways, lungs, blood vessels in and around the lungs, and the tissue covering the lungs (pleura).

The purpose of this research study is to evaluate patients referred to the Cardiovascular and Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to;

  1. Develop a better understanding of the causes and disease processes involved in disorders of the lungs
  2. Identify patients eligible to participate in other P-CCMB research studies

Condition or disease
Pulmonary Disease

Detailed Description:
The chronic lung diseases are those disorders associated with functional and/or structural derangement to the alveolar structures, airways, pulmonary blood vessels, pleura and/or mediastinum. The purpose of this project is to permit the comprehensive evaluation of patients referred to the Pulmonary Branch of the National Heart, Lung, and Blood Institute (NHLBI) in order to: (1) develop an understanding of the etiology and pathogenesis of these disorders; and (2) identify individuals who will be suitable candidates for other NHLBI protocols. Testing and procedures will only be performed when medically indicated for the purposes of making a diagnosis or obtaining information likely to be useful in the management of the subjects' disease or condition.

Layout table for study information
Study Type : Observational
Actual Enrollment : 6564 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Comprehensive Evaluation of the Etiology and Pathogenesis of Chronic Lung Disease (Screening Protocol)
Actual Study Start Date : November 18, 1984

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lung Diseases

Group/Cohort
Group 1
Pulmonary Patients



Primary Outcome Measures :
  1. N/A - Screening protocol [ Time Frame: 1 Visit ]
    Evaluate



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   7 Years to 90 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
patients being screened for lung disease
Criteria
  • INCLUSION CRITERIA:

Symptoms consistent with pulmonary disease.

May have family history of lung disease.

Patients with diseases of organs with known association with lung disease.

Ranging in age from 7 to 90 years old.

Pregnant and nursing women may participate in minimal risk procedures

EXCLUSION CRITERIA:

Persons with no clinical evidence of lung disease.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00001183


Locations
Layout table for location information
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
Investigators
Layout table for investigator information
Principal Investigator: Joel Moss, M.D. National Heart, Lung, and Blood Institute (NHLBI)
Additional Information:
Layout table for additonal information
Responsible Party: National Heart, Lung, and Blood Institute (NHLBI)
ClinicalTrials.gov Identifier: NCT00001183    
Other Study ID Numbers: 820032
82-H-0032
First Posted: November 4, 1999    Key Record Dates
Last Update Posted: October 14, 2020
Last Verified: August 27, 2020
Keywords provided by National Institutes of Health Clinical Center (CC) ( National Heart, Lung, and Blood Institute (NHLBI) ):
Computed Tomography
Fiberoptic Bronchoscopy
Pulmonary Function Testing
Cardiopulmonary Exercise Testing
Allergen Skin Testing
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Respiratory Tract Diseases